Yıl: 2021 Cilt: 37 Sayı: 1 Sayfa Aralığı: 24 - 31 Metin Dili: Türkçe DOI: 10.30733/std.2020.01475 İndeks Tarihi: 04-06-2021

Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi

Öz:
Amaç: Bu çalışmada akciğer kanserinin pozitron emisyon tomografi/bilgisayarlı tomografi (PET/BT)’denelde edilen primer lezyonun en geniş çapı (LEGÇ), maksimum standardize alım değeri (SUVmax),ortalama standardize alım değeri (SUVmean), metabolik tümör hacmi (MTV) ve toplam lezyon glikolizis(TLG) değerlerinin klinik evre ile ilişkisi incelenecektir .Hastalar ve Yöntem: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Nükleer Tıp Anabilim Dalında01.01.2012- 31.12.2014 tarihleri arasında PET/BT görüntülemesi yapılan, akciğer kanseri tanılı hastalarçalışmaya alındı. PET/BT görüntülerinden elde edilen LEGÇ, SUVmax, SUVmean, MTV ve TLG değerleriile histopatolojik alt tipler not edildi. Küçük hücre dışı akciğer kanseri (KHDAK) tanısı alan hastalar TNM(Tümör boyutu, lenf nodu, uzak metastaz) evreleme sistemi ile evrelendirildi. Küçük hücreli kanser (KHAK)tanısı alanlar sınırlı ya da yaygın evre olarak sınıflandırıldı .Bulgular: Yüz on sekizi erkek ve 12’si kadın toplam 130 hastanın, ortalama yaşı 63,46 ± 9,96 idi. Yüzaltı hasta (%81,5) KHDAK iken; 24 (%18,5) hastaya KHAK idi. KHDAK hastaların 62’si yassı hücrelikanser, 39’u adenokanser, 5’i diğer alt tiplerden oluşmaktaydı. PET/BT görüntülerinden elde edilen LEGÇ,SUVmean, SUVmax’ın ortalama değerlerinin, MTV ile TLG’nin ortanca değerlerinin KHDAK ile KHAKhasta grupları arasında anlamlı fark yoktu. Ayrıca bu parametrelerin KHAK’de evre ile ilişkisinin olmadığıda bulundu. KHDAK’de LEGÇ, SUVmax, SUVmean, MTV ve TLG parametrelerinin klinik evre ile ilişkiliolduğu saptandı.Sonuç: Küçük hücreli dışı akciğer kanserinde yüksek SUVmax, SUVmean, MTV ve TLG değerleri ileriklinik evreyi predikte etmektedir .
Anahtar Kelime:

The Relationship Between F-18 FDG PET/CT Parameters and Clinical Stage in Patients with Lung Cancer

Öz:
Aim: It was aimed to investigate the relationship of disease clinical stage between the maximum diameter of primer lesion (MDPL), maximum of standardized uptake value (SUVmax), mean of standardized uptake value (SUVmean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values derived from positron emission tomography/computed tomography (PET/CT). Patients and Methods: Lung cancer patients diagnosed histopathologically between 01.01.2012 and 31.12.2014 in Necmettin Erbakan University Nuclear Medicine Department of Meram Medical Faculty scanned for PET/CT for lung cancer diagnosis and staging, were included in this study. MDPL, SUVmax, SUVmean, TLG and MTV derived from PET-CT scanning and their histopathological subtypes, other clinical and radyological information of patients were noted. The non-small cell lung cancer (NSLC) were graded according to tumor diameter, nodal and involvement metastasis (TNM) staging system. The small cell lung carcinoma (SCLC) diagnosed were categorised as limite d or extensive stage. Results: In this study, the mean age of 118 men and 12 women, totally 130 patients, was evaluated 63,46 ±9,96. The patients were classified as 106 NSCLC (81.5%) ve 24 SCLC (18.5%). The histopathologically diagnosed NSCLC patients were consists of 62 squamous cell cancers, 39 adeno cancers, and 5 other subtypes. It was observed that there was no significant relationship between the MDPL, SUVmax, SUVmean, MTV and TLG values among SCLC. Additionally, it was also found that there was no correlation between these parameters with the SCLC stage. MDPL, SUVmax, SUVmean, MTV and TLG parameters were related with stage in NSCLC patients. Conclusion: Higher SUVmax, SUVmean, MTV, and TLG values of the primary tumor were predicting the more advanced clinical stage in NSCLC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. JTO 2007;2(8):706-14.
  • 2. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. JTO 2007;2(12):1067-77.
  • 3. Birim Ö, Kappetein AP, Van Klaveren R, et al. Prognostic factors in non-small cell lung cancer surgery. EJSO 2006;32(1):12-23.
  • 4. Duhaylongsod FG, Lowe VJ, Patz Jr EF, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Annals of Thor Surg 1995;60(5):1348-52.
  • 5. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80(6):1046-51.
  • 6. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83(5):918-24.
  • 7. Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130(1):151-9.
  • 8. Li M, Liu N, Hu M, et al. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer 2009;63(3):383-6.
  • 9. Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18 F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl 2012;39(1):27-38.
  • 10. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography improve outcome prediction in earlystage non–small cell lung cancer after surgical resection. Ann Surg 2013;257(2):364-70.
  • 11. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2018;68(6):394-424.
  • 12. Miwa K, Inubushi M, Takeuchi Y, et al. Performance characteristics of a novel clustered multi-pinhole technology for simultaneous high-resolution SPECT/PET Ann Nucl Med 2015;29(5):460-6.
  • 13. Chang H, Lee SJ, Lim J, et al. Prognostic significance of metabolic parameters measured by 18 F-FDG PET/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol 2019;145(5):1361-7.
  • 14. Hu WD, Wang H, Wang YB, et al. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. TQ J Nucl Med Mol Imaging 2019.
  • 15. Sahiner I, Atasever T, Akdemir U, et al. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer. Rev Esp Med Nucl Imagen Mol 2013;32(6):357- 63.
  • 16. Melloni G, Gajate A, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. EJSO 2013;39(11):1254-61.
  • 17. Chen HH, Chiu N-T, Su W-C, et al. Prognostic value of wholebody total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012;264(2):559-66.
  • 18. Dooms C, van Baardwijk A, Verbeken E, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. JTO 2009;4(7):822-8.
  • 19. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage nonsmall- cell lung carcinoma. JTO 2008;26(9):1459-64.
  • 20. Eschmann S, Friedel G, Paulsen F, et al. Is standardised 18 F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl 2006;33(3):263-9.
  • 21. Sachs S, Bilfinger TV, Komaroff E, et al. Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer. Clin Lung Cancer 2005;6(5):310-3.
  • 22. Yıldırım F, Türk M, Akdemir ÜÖ, et al. Küçük hücreli dışı akciğer kanserinde primer tümör metabolik aktivitesi ile lenf nodu ve uzak organ metastazı arasındaki ilişki. GMJ 2018;29:164-8.
  • 23. Zhu S-H, Zhang Y, Yu Y-H, et al. FDG PET-CT in non-small cell lung cancer: Relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev 2013;14(5):2925-9.
  • 24. Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009;15(7):2426-32.
  • 25. Zhu D, Ma T, Niu Z, et al. Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 2011;73(3):332-7.
APA EROL M, Önner H, TAŞTEKİN G (2021). Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. , 24 - 31. 10.30733/std.2020.01475
Chicago EROL MUSTAFA,Önner Hasan,TAŞTEKİN GÜNGÖR Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. (2021): 24 - 31. 10.30733/std.2020.01475
MLA EROL MUSTAFA,Önner Hasan,TAŞTEKİN GÜNGÖR Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. , 2021, ss.24 - 31. 10.30733/std.2020.01475
AMA EROL M,Önner H,TAŞTEKİN G Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. . 2021; 24 - 31. 10.30733/std.2020.01475
Vancouver EROL M,Önner H,TAŞTEKİN G Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. . 2021; 24 - 31. 10.30733/std.2020.01475
IEEE EROL M,Önner H,TAŞTEKİN G "Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi." , ss.24 - 31, 2021. 10.30733/std.2020.01475
ISNAD EROL, MUSTAFA vd. "Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi". (2021), 24-31. https://doi.org/10.30733/std.2020.01475
APA EROL M, Önner H, TAŞTEKİN G (2021). Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. Selçuk Tıp Dergisi, 37(1), 24 - 31. 10.30733/std.2020.01475
Chicago EROL MUSTAFA,Önner Hasan,TAŞTEKİN GÜNGÖR Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. Selçuk Tıp Dergisi 37, no.1 (2021): 24 - 31. 10.30733/std.2020.01475
MLA EROL MUSTAFA,Önner Hasan,TAŞTEKİN GÜNGÖR Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. Selçuk Tıp Dergisi, vol.37, no.1, 2021, ss.24 - 31. 10.30733/std.2020.01475
AMA EROL M,Önner H,TAŞTEKİN G Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. Selçuk Tıp Dergisi. 2021; 37(1): 24 - 31. 10.30733/std.2020.01475
Vancouver EROL M,Önner H,TAŞTEKİN G Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi. Selçuk Tıp Dergisi. 2021; 37(1): 24 - 31. 10.30733/std.2020.01475
IEEE EROL M,Önner H,TAŞTEKİN G "Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi." Selçuk Tıp Dergisi, 37, ss.24 - 31, 2021. 10.30733/std.2020.01475
ISNAD EROL, MUSTAFA vd. "Akciğer Kanserli Hastalarda F-18 FDG PET/BT Parametrelerinin Klinik Evre ile İlişkisi". Selçuk Tıp Dergisi 37/1 (2021), 24-31. https://doi.org/10.30733/std.2020.01475